- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02248233
Nimodipine for Treating Acute Massive Cerebral Infarction
Nimodipine for Treating Acute Massive Cerebral Infarction: a Randomized, Double-blind, Controlled Clinical Study
Massive cerebral infarction is an ischemic stroke caused by complete blockage of the internal carotid artery, middle cerebral artery, or their cortical branches. The widespread infarction, pathological severity and high fatality rate associated with massive cerebral infarction pose a major threat to affected patients. However, there is a lack of unified diagnostic criteria. Many researchers use Adams' classification, in which massive cerebral infarction is diagnosed when the following criteria are met: infarct size > 13 cm2; a major brain-feeding artery is involved; the focal site affects more than two cerebral lobes; infarct diameter line ≥ 3 cm in internal capsule of striatum.
Prolonged cerebral ischemia/reperfusion can induce complex secondary changes in brain tissue, so the use of neuroprotective agents is very important. Remarkable progress has been made over the last decade in understanding the protective effect of calcium antagonists against cerebral ischemia. In particular, the liposoluble dihydropyridine Ca2+ antagonist nimodipine selectively acts on cerebral vessels and neurons and can protect ischemic brain tissue, providing a new way of treating ischemic cerebrovascular disease.
Preclinical and clinical tests have shown that nimodipine has a protective effect on ischemic brain tissue, and indicate that patients should take the drug as soon as possible. However, there are no reports of double-blind, randomized, controlled clinical trials addressing the administration of nimodipine via intravenous drip within the time window for successful treatment of acute massive cerebral infarction.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the clinic, physicians are reluctant to use thrombolysis, Defibrase and anticoagulation therapy because of the severity of symptoms, poor prognosis, risk of hemorrhage and high fatality rate that occur with acute massive cerebral infarction. Nimodipine, as a selective Ca2+ antagonist, is highly liposoluble, effectively crosses the blood-brain barrier, selectively acts on intracranial blood vessels, and is an accepted neuroprotective agent that can be applied in the clinic. The aim of the present study is to perform a double-blind, randomized and controlled trial of the clinical efficacy and safety of nimodipine administered as an intravenous drip in the early stages of acute massive cerebral infarction.
Patients will receive nimodipine within 3 days of infarction onset. We will closely monitor the following: (1) Blood pressure and heart rate of the patient before treatment, since nimodipine is contraindicated in patients with hypotension and low heart rate. Where blood pressure is ≥ 100/80 mmHg and heart rate ≥ 60 BPM, nimodipine will be administered. (2) Speed of infusion. This should not be too fast; we suggest 1-2 drops per minute initially, increasing gradually until the drop in systolic pressure exceeds 10 mmHg. The average drip speed should be 6-8 drops/minute, and the fastest drip speed 10 drops/minute. (3) During the infusion, physicians should monitor adverse reactions such as headache, dizziness, flushing or sweating. If any occur, the infusion speed must be reduced. If the patients remain uncomfortable, nimodipine should be withdrawn. (4) Liver and kidney function should be monitored throughout nimodipine administration.
Although nimodipine is relatively safe, there is still a risk of some adverse effects, such as cardiovascular system reactions (blood pressure decreases, bradycardia, angina, and atrioventricular block), headache, dizziness, edema, and liver and kidney dysfunction. It is necessary to determine the optimal therapeutic time window and dose of nimodipine in multi-center, large-scale clinical trials.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- First onset at age ≤ 80 years, no other severe medical complications;
- Clear consciousness or mild disturbance of consciousness; paralysis of upper and lower extremities on one side with grade 0-3 muscle strength in paralyzed limbs;
- CT reveals early massive cerebral infarction (without cerebral hemorrhage or old infarction);
- Blood pressure within, or higher than, the normal range.
Exclusion Criteria:
- Clinical manifestations are noticeably improved before treatment;
- Disorders of consciousness, manifesting as severe lethargy or coma;
- Mild neurological deficits, such as pure sensory disturbances, ataxia, dysarthria, and hemiparesis;
- Severe hypotension (systolic pressure < 90 mmHg, diastolic pressure < 60 mmHg);
- Heart rate < 60 BPM; sinus bradycardia;
- Severe heart, brain or kidney dysfunction, or malignant tumor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Saline + citicoline
The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance.
Patients with complications will receive symptomatic treatment.
|
physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
Other Names:
|
Experimental: Nimodipine
The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period. Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment. |
Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neurological deficits
Time Frame: up to 90 days
|
Neurological deficits after stroke will be assessed using the National Institute of Health Stroke Scale scores
|
up to 90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Runhui Li, M.D., Central Hospital Affiliated to Shenyang Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Stroke
- Brain Infarction
- Infarction
- Cerebral Infarction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Nootropic Agents
- Cytidine Diphosphate Choline
- Nimodipine
Other Study ID Numbers
- FengtianH-RHL-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Infarction
-
All India Institute of Medical Sciences, New DelhiPostgraduate Institute of Medical Education and Research; Sanjay Gandhi Postgraduate... and other collaboratorsCompletedMiddle Cerebral Artery Infarction | Anterior Cerebral Artery InfarctionIndia
-
University of Roma La SapienzaNot yet recruitingMiddle Cerebral Artery Occlusion With Cerebral Infarction
-
Ege UniversityCompletedCerebral HerniationTurkey
-
Shanghai East HospitalRecruitingCerebral Infarction | Brain Infarction | Infarction, Middle Cerebral Artery | Stroke, Ischemic | Acute Stroke | Infarction, Anterior Cerebral Artery | Infarction, PCA | Infarction, Posterior Circulation, BrainChina
-
Assistance Publique - Hôpitaux de ParisTerminatedMalignant Middle Cerebral Artery InfarctionFrance
-
General Hospital of Shenyang Military RegionTerminatedMiddle Cerebral Artery InfarctionChina
-
Celularity IncorporatedCelgene CorporationTerminatedStroke, Acute | Middle Cerebral Artery Stroke | Posterior Cerebral Artery StrokeUnited States
-
University of AarhusCompleted
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownMiddle Cerebral Artery InfarctionMalaysia
-
University of the PhilippinesTerminatedInfarctionPhilippines
Clinical Trials on Saline + citicoline
-
Mclean HospitalWithdrawnTraumatic Brain InjuryUnited States
-
Emory UniversityNational Institute on Aging (NIA)Recruiting
-
Deborah Yurgelun-ToddCompletedNeurocognitive ImprovementUnited States
-
Ohio State UniversityRecruiting
-
Deborah Yurgelun-ToddWithdrawnTraumatic Brain Injury | Substance Abuse | Substance Dependence
-
Deborah Yurgelun-ToddCompleted
-
Armed Forces Hospital, PakistanUnknownHypoxic-Ischemic EncephalopathyPakistan
-
Fondazione G.B. Bietti, IRCCSCompletedGlaucoma | Optic Neuropathy, Ischemic | Optic Nerve | Visual Pathway Disorder | Neural ConductionItaly
-
Mclean HospitalNational Institute on Drug Abuse (NIDA)CompletedMarijuana AbuseUnited States
-
Istituto di Ricerca Neuroftalmologia S.r.l.Fondazione G.B. Bietti, IRCCSCompleted